Molecular Advances in Haematological Malignancies
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 20 January 2025 | Viewed by 3472
Special Issue Editors
Interests: multiple myeloma; haematological malignancies; mechanisms of resistance; targeted therapies
Special Issues, Collections and Topics in MDPI journals
Interests: multiple myeloma; clinical proteomics; biomarkers
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Haematological malignancies are a broad category of cancers of the hematopoietic system, including leukaemias, lymphomas, multiple myeloma, myeloproliferative neoplasias, and myelodysplastic syndromes. The mechanism by which haematological malignancies such as leukaemia, lymphoma, and myeloma develop and proliferate in vivo is not yet fully understood. Treatment approaches, in addition to allogeneic hematopoietic stem cell transplantation, include single- and bispecific-molecule targeted therapy, such as with CAR-T cells.
This Special Issue focuses on molecular advances in the treatment of haematological malignancies and specifically welcomes original articles and review articles covering critical signalling pathways, host immune responses, pathogenesis, and novel targeted therapies such as chemotherapy, immunotherapy, stem cell transplant, monoclonal antibodies, and CAR-T cells.
Dr. Despina Bazou
Dr. Paul Dowling
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- haematological malignancies
- multiple myeloma
- biomarkers
- tumour microenvironment
- genomics
- proteomics
- extramedullary myeloma
- therapy
- minimal residual disease
- smouldering myeloma
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.